Rate My Professor Jacques Ravel

Ravel's research program applies genomics technologies, ecological principles, metagenomics, metatranscriptomics, multi-omics, and bioinformatics to characterize the human microbiome, with a focus on the vaginal microbiome's dynamics and role in women's health, bacterial vaginosis, sexually transmitted infections such as Chlamydia trachomatis and HPV, and adverse pregnancy outcomes like spontaneous preterm delivery. He leads NIH-funded initiatives, including the Collaborative Research Center developing 3D biomimetic cervicovaginal models for studying sexually transmitted infections. Ravel co-founded LUCA Biologics in 2019 to develop live biotherapeutics targeting the vaginal microbiome. His honors include election to the American Academy of Microbiology in 2012 and the Blaise Pascal International Research Chair in 2015 at the Institut Pasteur. He is Editor-in-Chief of the journal Microbiome and Associate Editor of mBio. Key publications include 'Vaginal microbiome of reproductive-age women' (Proceedings of the National Academy of Sciences USA, 2011), 'Temporal dynamics of the vaginal microbiota' (Science Translational Medicine, 2012), 'Structure, function and diversity of the healthy human microbiome' (Nature, 2012), 'Cervicovaginal microbiota and local immune response modulate the risk of spontaneous preterm delivery' (Nature Communications, 2019), and 'Impact of a multi-strain L. crispatus-based vaginal synbiotic on the vaginal microbiome' (NPJ Biofilms and Microbiomes, 2025). With over 300 peer-reviewed publications, Ravel has significantly advanced translational microbiome science.